
Seizing Unexpected Medtech Opportunities
Interview with Ablative Solutions CEO Kate Rumrill
About the Guest
Kate Rumrill, CEO of Ablative Solutions, is an accomplished leader with over three decades of comprehensive experience within the medical device and pharmaceutical industries. She brings a unique blend of expertise to the table, spanning roles from clinical affairs to executive management, with pivotal stints at prominent companies such as Eli Lilly & Company and Covidien.
Interview Summary
Kate Rumrill, CEO of Ablative Solutions, has navigated a unique path to the C-suite with over 30 years of experience in the medtech and pharmaceutical industries. Initially interested in a career in neurosurgery, Kate’s coincidental foray into toxicology research during her gap year eventually led to her professional future in the medtech space. Her journey is a testament to the power of seizing unexpected opportunities and embracing the twists and turns that often shape our careers.
Kate’s initial work as a pharmaceutical researcher spawned new opportunities, starting with toxicology research and gradually expanding into clinical affairs, medical affairs, reimbursement, and executive leadership. By gaining experience in various industry functions, Kate acquired invaluable insights into strategy and tactical planning and became familiar with the intricacies of both the clinical and commercial aspects of a medical device company.
Kate’s leadership journey includes roles as President and CEO of NeoSync and Vice President, Global Medical Affairs of Covidien’s Peripheral Vascular Division. These experiences helped further refine her expertise in product development, clinical strategy, financial management, and commercial product launches.
Currently, Kate is leading the charge at a clinical-stage medical device startup specializing in transcatheter perivascular alcohol denervation for hypertension treatment.
The company has pioneered the Peregrine System to perform chemical renal denervation using alcohol as a neurolytic agent. Their solution uses a proprietary catheter to deliver a neurolytic agent — alcohol, in this case — into the perivascular space, which sets the device apart from other energy-based technologies in the market.
Key Learnings From Kate’s Experience
Sustained success in medtech requires three ingredients: thorough research, a deep conviction in your technology, and a complete understanding of its potential impact on patients’ lives.
When designing clinical trials, you must take into account the required capital, regulatory compliance, and end-user experience. This involves engaging with the right stakeholders, investors, regulators, and practitioners early on to preempt potential issues and future-proof the trial design.
A comprehensive understanding of your technology's unique landscape is crucial to devising a successful reimbursement strategy. Your plan must be comprehensive and articulate, as investors are interested not just in the technology but in how it will get paid for.
Leaning Into and Leveraging Personal Drive
The medtech terrain is often risky, challenging, and fraught with uncertainty. Yet, for seasoned industry leaders like Kate, these are the very elements that catalyze innovation and opportunity.
Having held influential roles at Covidien, NeoSync, and, currently, Ablative Solutions, Kate's career journey offers essential insights into leveraging strategic pivots to ascend the professional ladder.
Some of the most important things for professional success, according to Kate, are having a comprehensive understanding of your product along with a deep belief in the technology you’re working on. More than merely understanding a company's position, Kate underscores the need for personal conviction in the technology's potential to impact patients’ lives. In her case, both of her parents struggle with hypertension and aren’t fond of taking their medications. This personal background reinforced her drive to explore medical devices for this particular problem.
When stepping into unknown territories, Kate posits that understanding the medical need and having a vested interest in your target illness is crucial. She explains: "What is the unmet medical need and what are you trying to do there? I always try to think about that."
Despite facing skepticism, Kate's conviction in the potential of renal denervation led her to join Ablative Solutions. Her belief was anchored in expert opinions, a nuanced understanding of hypertension, and meticulous scientific evaluation.
The critical lesson learned was understanding the real-world implications and having realistic expectations of a technology developed for treating a complex medical condition like hypertension. She says: “Hypertension is a lifelong illness, and it's very complex because it's not just what's going on with your sympathetic nervous system. It's diet, it's exercise, it's lifestyle. All of those sorts of things factor in.”
Overall, Kate’s experiences underline the value of extensive research, personal connection, realistic expectations, and a firm belief in the technology you’re developing.
Devising a Strategic Clinical Trial Design
The medtech realm is a highly competitive space. And one thing to keep in mind is that the best technology doesn’t always win. A great product blueprint is only as good as its reach and utilization. It’s also critical to ensure your product aligns with the available reimbursement mechanisms.
The lesson here is straightforward: you need to factor in all the different aspects of your product when designing clinical trials. Fundraising, regulatory expectations, and end-user experience should not be afterthoughts but guiding forces from the inception of the business plan. A failure to do so, or postponing these aspects to later stages, can potentially derail your venture before it even takes off.
To successfully navigate all of these key arenas, Kate advises consulting with the right people early on. In her words: “You need to be looking ahead, and you need to be looking around the corner when designing your clinical trial because after it’s implemented, it's too late to make significant changes.”
The right people she’s referring to are investors, regulatory stakeholders, and practitioners. When you involve experts from diverse aspects of the product’s life cycle, proactively addressing the potential questions that may arise in the future, you can ensure your clinical strategy is built on a robust foundation.
Do Your Reimbursement Homework or Suffer the Consequences
When stepping into the world of medtech startups, predicting the unpredictable is a core tenet of success. As Kate bluntly states: "You need to constantly be challenging yourself and thinking about the what ifs." The industry is dynamic, and unexpected hurdles are more of a certainty than a possibility.
What distinguishes successful medical device entrepreneurs, according to Kate, is their capacity to adapt in the face of these unforeseen circumstances. Based on her experiences, preparing for the unexpected comes down to one thing – thorough homework.
Kate explains that reimbursement strategy is not a one-size-fits-all concept. "It's hard to give general advice because reimbursement is so different depending on the technology," she shared. That is why understanding the unique landscape of your technology is crucial, and it's a question investors will certainly ask.
"You have to have a strategy, know what the landscape is, and know what your plan is at least at the 30,000-foot view because you're going to get asked about it," she advised. No investor wants to see a deer-in-headlights look when they ask, "Who's going to pay for this technology that you're developing?" Having at least an overarching strategy can be the difference between walking away with or without a check.
From her days at NeoSync, where she cut her teeth in fundraising and perfected her pitch, to her current role at Ablative Solutions, Kate understands that investors are looking for more than just a compelling product — they want to see a roadmap to success that includes a thoughtful reimbursement strategy.
Sponsors
FastWave Medical: Named MD+DI's Company of the Year, FastWave is one of the hottest medtech startups in the cardiovascular space. See how you can invest here.
Fundraising Cohort: Planning to raise capital for your startup? This live, 4-week workshop, led by Scott Nelson, is designed to help founders and CEOs tell a sharper story, get investor meetings that matter, and close real capital. Join the waitlist here.
Don’t Forget
Interested in advertising with us?
Get in Touch →
Want to learn from more startup CEOs?
Check Out the Archive →
Forwarded this email?
Join for Free →
Who's Scott Nelson again?
See His Bio →
Transcript
0:00:00 [upbeat music] Never to assume that things are gonna go as planned. Mm. Um, and always to, to be thinking about contingencies and, um, as I like to say, looking around the corner.
0:00:13 What's the next challenge gonna be, and what can we do to make sure that we have a plan B, uh, just in case things don't go as planned?
0:00:20 Welcome to MedSider, where you can learn from the brightest founders and CEOs in medical devices and health technology.
0:00:28 Join tens of thousands of ambitious doers as we unpack the insights, tactics, and secrets behind the most successful life science startups in the world. Now, here is your host, Scott Nelson. [upbeat music] Hey, everyone.
0:00:41 It's Scott. In this episode of MedSider, I sat down with Kate Rumrill, CEO of Ablativ Solutions.
0:00:46 Kate is an accomplished leader with over three decades of comprehensive experience within the medical device and pharmaceutical industries.
0:00:52 She brings a unique blend of expertise to the table, spanning roles from clinical affairs to executive management, with pivotal stints at prominent companies such as Eli Lilly and Covidien.
0:01:01 Here are a few of the key things that we discussed in this conversation.
0:01:04 First, sustained success in med tech requires three ingredients: thorough research, a deep conviction in your technology, and a complete understanding of its potential impact on patients' lives.
0:01:14 Second, when designing clinical trials, you must take into account the required capital, regulatory compliance, and end user experience.
0:01:21 This involves engaging with the right stakeholders, investors, regulators, and practitioners early on to preempt potential issues and future-proof the trial design.
0:01:30 Third, a comprehensive understanding of your technology's unique landscape is crucial to devising a successful reimbursement strategy.
0:01:37 Your plan must be comprehensive and articulate, as investors are interested not just in the technology, but in how it will actually get paid for.
0:01:45 Before we jump into this episode, I wanted to let you know that we just released the latest edition of MedSider Mentors, volume three, which summarizes the key learnings from the most popular MedSider interviews over the last several months, with folks like Jim Pursley, CEO of Hinge Health, Carol Burns, CEO of Cagent Vascular, and other leaders of some of the hottest startups in the space.
0:02:06 Look, it's tough to listen or read every MedSider interview that comes out, even the best ones, but there are so many valuable lessons you can glean from the founders and CEOs that join our program.
0:02:15 So that's why we decided to create MedSider Mentors. It's the easiest way for you to learn from the world's best medical device and health technology entrepreneurs in one central place.
0:02:24 If you're interested in learning more, head over to medsiderradio.com/mentors. Premium members get free access to all past and future volumes.
0:02:33 If you're not a premium member yet, you should definitely consider signing up. In addition to every volume of MedSider Mentors, you'll get full access to the entire library of interviews dating back to 2010.
0:02:43 This includes conversations with experts like Nadim Yarib, CEO of CVRx, Renee Ryan, CEO of Cala Health, and so many others. Learn more by visiting medsiderradio.com/mentors. [upbeat music] All right, Kate.
0:03:00 Welcome to MedSider Radio. Thanks for having me. Yeah, this should be a fun conversation, right?
0:03:04 I mean, we get to sort of r- relive some, some old times, uh, together at, at Covidien and, and Medtronic, and learn a little bit more about, uh, you know, what you're up to, uh, at, uh, at Ablativ Solutions.
0:03:13 So it'll be a fun conversation. So let's start there, though. Um, if you can...
0:03:17 You know, I recorded a brief bio at the outset of this interview, but, um, let's go back in time a little bit, maybe not through every single career move.
0:03:23 But if you can kind of give us your, the, the sort of the, the quasi-expanded elevator pitch for, uh, you know, Kate Rumrill's, uh, you know, professional journey in, in med tech. Yeah, absolutely. Happy to.
0:03:33 You know, I think for me, I'm a little bit unique, uh, in how I came to the C-suite, how I came to be a CEO. I actually, you know, started off with my undergrad thinking that I was gonna be a neurosurgeon.
0:03:47 So I did, I was pre-med undergrad, and took a gap year, uh, and, and fell into a summer job working in research for a pharmaceutical company, and here I am 30-plus years later.
0:04:00 Never quite made it to medical school, but, um, have had an interesting, uh, career with lots of twists and turns. I actually came up through the research side of things.
0:04:12 So unlike a lot of my peers, uh, I started off doing toxicology research, and then I crossed over into clinical affairs with, you know, my, um, my role expanding into medical affairs, reimbursement, uh, all those sorts of things.
0:04:28 Uh, and then being part of executive leadership teams where we, you know, I had visibility across, uh, strategy and, uh, tactical plans, not just within the clinical world, but, you know, across the business.
0:04:43 And I think those experiences really prepared me for a CEO position, especially for early, early-stage product development companies. Mm-hmm. So it's been a fun ride. Yeah.
0:04:55 And, and I, um, we had the chance to kind of loosely work with each other at, at, at Covidien and- Yeah...
0:05:00 and Medtronic during my time, and I always remember, um, you were almost involved in almost every single sort of functional, you know, larger functional initiative. I was like, "Why, why is Kate always like..."
0:05:09 [laughs] Everyone's like, you know, "Is Kate coming to this meeting, or is Kate involved?" And, but, but I think, I think that speaks to that, right?
0:05:14 Of like you were involved in so many different aspects of the business. You saw, you saw so much, right? Mm-hmm. What worked, what didn't, how to, you know, build synergy across different, different groups, et cetera.
0:05:22 So I got, I gotta think that's probably been pretty instrumental as you, uh, as you, as you've kind of, uh, you know, built your own companies and are now leading them as, as CEO. Yeah. Absolutely. Yeah.
0:05:32 Yeah, I mean, y- you, you can't be an expert in everything. You need to surround yourself with, uh, talented people who know what they're doing and empower them to get things done.
0:05:41 But you need to at least know the basics. Mm-hmm.
0:05:44 You know, I don't claim to be a, a marketing expert, but I know enough about what needs to be done so that, you know, my, my marketing team can, uh, can have the support that they need in order to, to do things and do things well.
0:05:57 Yeah, that, no doubt. I, I, uh, recently had Carol Burns on the program. She's the CEO of Cagent. You're probably familiar with Carol, and she made a very similar comment.
0:06:04 She's like, you know, one of the most important things that she's learned as CEO is, like, you, you just, you need to- Recognize and be sort of intellectually honest about y- your gaps, right?
0:06:11 You're gonna have, you know- Mm-hmm... you're gonna have your wheelho- you, you certain, certain areas that, you know, are, are in your wheelhouse or, or your core strengths.
0:06:16 But you need to understand, like, some areas, you know, y- you know enough, you should know enough to kind of be dangerous, but that means you, you need to bring in the right people, right?
0:06:23 To kind of, you know, really, really shore up some of those gaps. So, um, so I'm, I'm right, I'm right there with you. Let's, let's talk a little bit about Ablativ at a high level, and then we'll certainly- Sure...
0:06:32 ki- kind of go back in time to kind of learn a little bit more about the company's journey, um, and, and just things that, that you've learned, yeah, as, as, as the company's kind of evolved and, and developed and, and grown up.
0:06:42 But let's start high level. What, what is... Tell us a little bit more about the technology, you know, what, what it is and then, like, how it, uh, it came to be. Yeah, sure.
0:06:50 So, um, Ablativ Solutions w- uh, is a renal denervation company. So we're developing a, uh, treatment. Our first indication will be hypertension or the treatment of hypertension, um, for patients who are uncontrolled.
0:07:03 Uh, in other words, they're taking antihypertensive meds and their blood pressure is still not within the guidelines.
0:07:09 And so, um, for those that aren't aware of renal denervation, uh, it's basically a catheter-based, um, systems where you go into the renal artery and you ablate the nerves in the space around the renal artery.
0:07:25 And in doing so, basically what you're doing is you're cutting off an over-signaling of the sympathetic nervous system which is what causes high blood pressure in many patients.
0:07:35 And so there are a few other, uh, therapies that are out there, energy-based devices that, uh, are in FDA review right now.
0:07:44 We're about a year behind them with what we think is a novel, uh, mechanism or a novel way of, um, achieving this denervation.
0:07:53 We actually use our proprietary catheter that delivers a neurolytic agent into the perivascular space as opposed to energy. So our neurolytic agent of choice is alcohol.
0:08:08 Uh, and so we infuse.6 milliliters of ethanol into the perivascular space, uh, around the main renal arteries, and then we can treat up to accessories if need be, if they're large enough, um, not to ignore.
0:08:23 And, uh, in so doing, we, uh, create this cloud or this cylinder around the artery where all of the nerves run, and, uh, we ablate the nerves. In- interesting. That's really cool.
0:08:34 And so, still e- even though you're delivering, you know, alcohol as sort of the, the, the agent to sort of a- a- ablate these nerves, it's st- it's still a device, right? It's not a device- Mm-hmm... drug combo.
0:08:43 Well, technically, it's a combination product. Oh, it is. Okay. So, um, we have 510[k] clearance and CE mark for the catheter as a, um, a device that infuses neurolytic agents, you know, in, into the body.
0:08:59 Um, but what we're working on right now is the approval of the device with our alcohol, um, which technically is considered a drug.
0:09:09 And so, uh, it's a combination product, but it's actually an NDA approval process through the FDA. Got it, got it. Okay. That's, that's super helpful.
0:09:19 You, you mentioned that you're about a year behind, right, some of these other, uh, startups in the, um, uh, denervation space.
0:09:24 But can you give us a sense for kind of where that c- the company is specifically, um, in terms of, you know, plan, reg, and, you know, maybe even eventual, you know, commercialization? Yeah.
0:09:34 So we just press released, um, a c- few weeks ago that we've completed enrollment in our pivotal trial. It's called the TARGET-BP1 trial.
0:09:43 Um, this is in, as I said, patients with uncontrolled hypertension taking two to five medications. And, uh, so we completed enrollment in that.
0:09:53 The primary endpoint is three months, but we keep the study blinded out to six months, uh, so that we can also monitor medication uses, uh, uh, of these patients longer term and then of course long-term sa- longer term safety.
0:10:09 And so we're in that follow-up phase now. We anticipate, uh, completing the six-month follow-up for the last patient, it was a 300-patient study, by the end of the year, and then we'll be doing the data analysis.
0:10:23 All going well, we should be submitting to FDA by Q2 of next year. Got it, got it.
0:10:28 We're recording this in, you know, kind of mid-2023-ish to, to help kind of level set everyone that's, uh, that, that's listening, um, after, after the fact. So that's really helpful.
0:10:38 Um, for those listening that don't get a chance to, to, um, uh, read the full, uh, summary art- article that o- on MedCity that, that'll accompany this, this particular episode and you want to learn a little bit more about the technology and the company, website is Ablativ Solutions, uh, just as it sounds, ablativsolutions.com, and you can go and check out the, the technology in a little bit, a little bit more detail.
0:10:57 Uh, um, but let's, uh, if it's okay, Kate, let's move on to the, the substance of the discussion, right? You mentioned renal, renal denervation.
0:11:04 I think for anyone that's listening to this that's familiar with the cardiovascular space, uh, they're aware of Ardian, right? Mm-hmm.
0:11:10 And, um, even if you don't have, like, an in-depth understanding of that story, it's, it's, it's super interesting at a, at, at a high level. Pretty... They were pretty early on.
0:11:17 Medtronic came in, monster acquisition, and it really hasn't gone anywhere, I think, for, you know, maybe, maybe that's the, the best way to describe it, or at least, at least at a high l- [laughs] at a high level.
0:11:26 And so looking at your career, and we chatted about this a little bit before I hit the record button, you've been-- you've had a really unique experience in the sense that you've, you've s- sort of had two different boomerang stories, right?
0:11:35 Mm-hmm. With Covidien and then NeoSync. So I'd love to kind of get your take on that.
0:11:39 But then, but then if I'm in your shoes and I'm considering, you know, what's my next move after NeoSync and, you know, you're looking at Ablativ, you know, a lot of people would be a little bit scared to make that move, right?
0:11:49 I mean, renal denervation can maybe comes with some, some negative, you know, uh, co- context. But you obviously saw something different.
0:11:55 You saw some, some promise here, and you obviously have a really, really strong clinical background.
0:11:59 So love to learn a l- just a little bit more about that thought process and, you know, maybe frame it up for other people that, that could be in a similar boat where, you know, it's a good, seems like a good career opportunity but The space seems maybe a bit risky, you know?
0:12:11 So, yeah Right... I'd love to get your thoughts on that. Yeah. Yeah, and I think it's a really good question. Um,
0:12:16 certainly as you're pondering your next move, whether it's a CEO role or any other position for that matter, you really need to do your homework.
0:12:24 And at least for me, I've always, when I've been making those decisions, I always factor in, do I believe in the technology? Do I have a vested interest in the disorder or the disease that is being treated?
0:12:42 In my case, both my parents, uh, have struggled with hypertension and ha- hate taking their medications, and I have to yell at them all the time.
0:12:52 And, you know, what is it, w- what is the unmet medical need, uh, and what are you trying to do there? And so I always try to think about that.
0:13:00 And then of course, I look at the company, the people, because you spend a lot of time together, and, you know, are, are you gonna enjoy that journey together and, and are you gonna be able to come together and, and really work as a team?
0:13:13 Um, which is, you know, obviously critically important as well. You can get a job anywhere, but, you know, you have to really love what you're doing and believe in what you're doing.
0:13:21 In the case specifically of renal denervation and Ablative Solutions, y- y- you know, you, you nailed it. It, it's has had, this space has had an interesting journey. Mm-hmm.
0:13:32 Um, I myself was there, uh, front row and center. Uh, at Covidien, we had our own renal denervation product called One Shot that was acquired by Mayo Medical.
0:13:43 And, you know, back in 2011, 2012, it was, you know, gonna be the next big thing. Everybody had a product that they were developing. But as you mentioned, even Ardian, it was very early.
0:13:58 You know, people were doing first in-man studies, and we really, I don't think, had a, a good grasp or understanding of renal denervation and the mechanism behind it, but also how complicated hypertensive patients are to study in a clinical trial.
0:14:15 Hmm. And so, you know, 2012 was, uh, you know, April of 2012 was when Hypertension 3 came out, and all the companies really reevaluated and said, "Hmm, let's take a pause here."
0:14:30 And, you know, fast-forward for me then to 2014 when Covidien was acquired by Medtronic and I was approached to take on the CEO position at NeoSync, I stepped out of the vascular space for a while, for obvious reasons, for a couple of years.
0:14:46 And I was kind of keeping tabs on things that were going on in the space, but I wasn't, you know, living and breathing, uh, things that were going on in the cardiovascular space.
0:14:57 So fast-forward to 2019 when Ablative Solutions approached me to come and join them as CEO. Of course, my first response was, "Wait, I thought we killed renal denervation back in 2012."
0:15:09 [laughs] And so then, you know, I started reading up on it and doing my homework, and, and what I found was that not only Medtronic and, uh, you know, other companies, but really the KOLs, the leading experts in this space that understand hypertension and understand the mechanism behind why renal denervation does work and should work, they took the time to really evaluate what is the appropriate expectations for an intervention such as this.
0:15:45 Because back in 2011, 2012, there was this belief that renal denervation was gonna cure hypertension. Well, hypertension's a lifelong illness. Hmm. Um, and it's very complex, right?
0:15:58 Because it's not just what's going on with your sympathetic nervous system, it's diet, it's exercise, it's lifestyle. Um, all of those sorts of things factor in, and then also it's a progressive disease.
0:16:10 And so to think that you could treat somebody with a renal denervation procedure and they never have to take a pill again in their life, um, they can ta- they're taking seven pills and they're never gonna have to take another pill, that was just unrealistic at the time.
0:16:28 The other thing I think that, that was learned during that time was how to design these trials, because clinical trials are difficult in and of themselves, but to do it in a hypertensive population where we know that more than 50% of patients are not compliant with taking their meds,
0:16:49 and we need them to be stable and taking their medications consistently because if you don't, in a randomized control trial, you don't know how much of it is medication influence and how much of it is truly related to renal denervation.
0:17:03 Hmm. So through this, the KOLs came up with kind of a template of the appropriate protocol that actually all the companies now follow. Hmm.
0:17:13 We, we measure ambulatory blood pressure for 24 hours to get a more, uh, consistent measure of blood pressure as opposed to just a single, uh, measurement in the physician's office.
0:17:26 We track compliance that the patients are actually taking their medications. Um, and so very methodical in, in, you know, thinking through what these protocols look like.
0:17:38 I will tell you they are not easy to run- [laughs]... um, having just completed our pivotal trial enrollment. But, um, you know, I think it's,
0:17:47 it, the, the, um, scientific community has done their best to really, um, try to take the noise out of the data sets the best that we can under the circumstances, uh, in this difficult population. Got it.
0:18:01 And I, uh, that's such a great, uh, background. And I forget that you were that closely involved with the space back at Covidien. Um, you mentioned- Mm-hmm... Mayo Medical.
0:18:10 [laughs] I al- I almost forgot about that acquisition.
0:18:12 Um- Uh, so, so when you were, when you were, you know, sort of digging into Ablative, you obviously had a certain level of familiarity, not a certain level, a pretty deep level of f- of familiarity with the space.
0:18:21 But my understanding of, you know, without kind of be- you know, um, I guess getting too far into the weeds with renal denervation, I, I, I sort of, uh, you know, loosely understood that a, a lot of the, the challenges were related to clinical trial design and actually running an effective clinical trial.
0:18:33 But it, it sounds like it was, um, it was dynamic though, right? There's like these issues with how to, how do you effectively run a, run a trial to demonstrate, you know, efficacy.
0:18:41 Probably some of the issues were related to the, the technology itself, right? You know- Yeah...
0:18:45 energy versus like what you're, what you're working, uh, on at, at Ablative, you know, and then you've got like these maybe wild expectations, as you mentioned, that, um, that are probably not, uh, not rooted in, in reality.
0:18:55 Mm-hmm. And so those didn't scare you away. You were... You know, it s- it sounds like, uh, you know, you... There's enough of a, a sort of a, a, a personal sort of story,
0:19:03 plus your, your kind of your, uh, your expertise in the space already that, you know, that you were like, "You know, this maybe comes with a little, a little bit of risk, but I, I'm okay with the, the risk, you know."
0:19:12 Yeah. "I, I, I'm a, I'm a believer in the space." Yeah, absolutely.
0:19:15 And, and I, I guess I'll close that thought on, uh, you know, so I kind of re-educated myself on what had transpired, um, you know, during that timeframe.
0:19:25 Of course, Medtronic had done additional studies with their next generation catheter, saw some really good results,
0:19:31 and Ablative Solutions also had done their first in man and some early, uh, open label work, uh, where the, the, um, results were quite compelling.
0:19:41 And so as I started talking more to the investors and, and the management team of Ablative Solutions and really started to understand the technology itself, that's where they, they really got me.
0:19:53 Um, because, you know, I'm very familiar with RF energy. Obviously, during my time at Covidien, we had closure fast for, you know, for, for venous, uh, disorders.
0:20:03 Um, and then of course, you know, uh, specifically in the renal denervation space. But what we have at Ablative Solutions, in my humble opinion, is a pretty cool technology.
0:20:14 So, you know, we are not imposing energy through the media.
0:20:19 We're inserting microneedles through the media into the perivascular space, and we are, uh, exposing the nerves exactly where they are located, um, in that perivascular space to this neurolytic agent.
0:20:34 Um, it's a simple catheter to use, and it's one and done, so it's a single infusion per artery.
0:20:40 Uh, so it takes the guesswork out for the physicians who, you know, they don't have to question, "Am I in the right location? Did I get the, the ablation correct?" It's, it's a single infusion, takes about a minute each.
0:20:55 Got it. Yeah. So it's definitely distinct technology, right? Yeah. So you're solving for that, sort of that, that gap with other energy-based platforms.
0:21:01 And, and j- just to clarify, is it, is it largely interventional cardiologists that are, that are performing the procedure then? Yes. Okay. Okay. Yeah. That's, that's what I, that's what I expected. Um, well, cool.
0:21:09 No, it sounds like... I, and I don't think I was fully aware of sort of the, the underlying sort of mechanism, right, of, of the, your technology at, a- at Ablative, but it sounds, sounds, uh, super interesting, right?
0:21:18 So with this microneedling approach, right, being able to sort of better infuse, you know, um, this, this agent, right, alcohol, uh, to, to ablate the, ablate the nerve sounds like, uh, sounds like you're onto something.
0:21:30 Yeah. Yeah. Oh, well, cool. That's awesome.
0:21:32 And, and, and just to kind of close the, the loop on this, this kind of career to- topic that we started out with, you mentioned before we hit the record button about this, this boomerang, right?
0:21:39 And I touched on it just, just briefly, this, the kind of this, this double boomerang, uh, i- in your career.
0:21:43 But I, I'd love to get your, your, your thoughts, because I think that they're super helpful for most people that are, that are gonna be listening to this.
0:21:48 Um, and you, you mentioned something about, you know, just, you know, being very cognizant of keeping relationships intact, not burning bridges.
0:21:55 Maybe just touch on that before we kind of move to the next, next major topic, which is clinical affairs, which I, I, I wanna, wanna make sure we leave enough time, because that's, that's obviously, you know, one of your, one of your, uh, you know, key strengths.
0:22:04 But yeah, just maybe touch on that, because it, it is unique in the, in the fact that you've been at two companies, you know, twice now. Um, so- Yeah... yeah, I would love to get your, your take on that.
0:22:13 Yeah, absolutely. So a- as you mentioned, we were chatting before you hit the record button.
0:22:17 I was with a company that was acquired by Covidien, uh, in, in one of their divisions, and, uh, left the ac- uh, left Covidien after successfully, uh, making the transition, uh,
0:22:32 with the, the acquisition, uh, and went to a- another company called NeoSync that was in the neuromodulation space.
0:22:39 I joined that company as their second employee, helped them, you know, get all of their SOPs written, uh, a protocol through FDA, uh, hired a team, uh, and started the clinical trial.
0:22:51 And then it was at that point Covidien called me and said, "Would you be willing to come back?" This is about 18 months later. "Would you be willing to come back in the vascular space?"
0:23:00 And, um, you know, never would I thought, have thought, uh, you know, 10, 20 years ago that I would work for the same company twice.
0:23:10 But, you know, they came to me with a really compelling offer that, uh, with, um, a portfolio. They had just acquired EV3.
0:23:19 Um, and it was, it was, um, really intriguing and interesting for all the reasons I mentioned earlier of what I look at when I, uh, when I'm looking at, at making a move. And so I made the decision.
0:23:29 Um, I felt like I was leaving NeoSync in good hands because I had done pretty much everything they needed me to do. Um, and now it was just waiting for, as I like to say, the souffle to cook- [laughs]...
0:23:40 which is to complete the clinical trial.
0:23:43 And so I went back to Covidien and, um, uh, you know, several years had passed, and then the Covidien-Medtronic, uh, merger or acquisition, uh, occurred, and that's when the chairman of NeoSync called me and said, "Hey, uh, we'd like you to come back, and, uh, we want you to come back as the CEO
0:24:06 Hey, everyone. Let's take a quick break to catch you up on FastWave Medical, the company I co-founded and lead as CEO.
0:24:12 We're developing multiple intravascular lithotripsy systems, or IDL for short, for a market size of over $10 billion.
0:24:18 So you may remember the exclusive round of capital I told you we were going to carve out for FastWave insiders in the cardiovascular space.
0:24:24 Well, due to the overwhelming demand, we blew through our cap in just a few weeks and had to close it down much earlier than expected.
0:24:30 The incredibly high interest in this exclusive fundraise exceeded even our own expectations. But in retrospect, it sort of makes sense. Here's why.
0:24:37 First, Shockwave Medical, which is the only IDL player in town, has a market cap of close to $10 billion.
0:24:43 Second, we've designed FastWave systems to be faster, better, and more efficient, and to disrupt this monopolized category by giving physicians more IDL options to choose from.
0:24:52 Third, we've already secured two non-provisional patents from the USPTO, one of which was granted in six months, which is almost unheard of in the med tech space.
0:25:00 We may open up another private fundraise in the future, so if you're interested in joining our waiting list to invest in one of the hottest cardiovascular therapies, head over to fastwavemedical.com/invest and enter your email.
0:25:10 Again, that's fastwavemedical.com/invest. All right, let's get back to the rest of the conversation. And so again, I said, "Well, you know, I was already there once," uh, et cetera, et cetera.
0:25:21 And they said, "No, no, we, we really want you to come back and, and take on this role."
0:25:25 And so as we were discussing before you hit record, you know, I often, uh, talk to people I'm mentoring and, you know, even my own kids and, who are, uh, uh, early career and their friends.
0:25:37 You never burn a bridge, um, and you never say never because you just don't know what opportunities are gonna be afforded to you, and, and th- there's, uh, when you leave a company, it doesn't necessarily mean it's forever.
0:25:50 Mm-hmm. Yeah, yeah. That, it's, it's so important and I, and hopefully that, that resonates with, right, a lot of people that are, that are listening to this because when I...
0:25:56 After, like, looking at sort of that, that timeline, right? You- Mm-hmm... your company was acquired by Covidien, right?
0:26:01 Most startups that are acquired, they, you know, they rub people the wrong way, can kind of get a little, you know, there's, there's some, a lot of friction, right, through that- Yeah... that integration process.
0:26:09 But clearly you managed through that effectively, right? For Covidien to kind of want, want to, you know, sort of, like, welcome you back to the team. And I think that's really important, right? Because I don't...
0:26:17 I, I look at myself and it's like, well, I don't know, I, I could have probably got frustrated, you know, through an integration like that and let- Yeah... the frustration get the better of me, et cetera.
0:26:24 And obviously you didn't, and I think it's just really important and, and, and obviously that's just, like, one part of that, that story, right?
0:26:30 And with your time at NeoSync, right, you obviously left on g- re- like, really good terms for them to want you to come back after, you know, you know, spending only 18 months there.
0:26:39 To the, then run the company as CEO, you know, shortly, uh, you know, within, within a handful of years. And I, my hunch is that it's an intentional effort, right? It's not something that- Mm-hmm...
0:26:47 you know, you just, you can just kind of, you know, meander your way through that process. It's intentional about, like, making sure relationships are left on a good terms.
0:26:55 You're doing everything kind of within your control to- Mm-hmm... uh, to do what's, what- what's best by the, by, by the company and by, you know, the people that are, you know, running those companies.
0:27:02 And so I just think it's a, it's a really good reminder, you know? So. Yeah, absolutely. Yeah, and in the case when I left, uh, Covidien for the first time, it was actually for personal reasons.
0:27:10 I had a daughter that was starting high school, and the division that I was working with was based in Boulder and- Mm... you know, they needed me in Boulder. Mm.
0:27:18 And I wasn't gonna uproot her, uh, when she was starting high school, uh, and, and move her. Although, in hindsight, she probably would've really loved living in [laughs] Boulder. [laughs] Right. But, yeah.
0:27:28 But she was pretty well-grounded, you know, with her friends and, and, uh, and her schooling, so. Yeah. You know, at that time, as a mom, you know, I, I put family first. And, um, sometimes you have to do that. Mm-hmm.
0:27:40 And, and it's okay.
0:27:41 And to your point, I think the key is that you're open and you're honest about it, and if you do a good job and you leave your position in a better place than it was when you, when you entered that position,
0:27:59 then, you know, the- Yeah... the rest is, is kind of history. Right. Right. Yeah, let the, let the chips fall, you know, as long as you're just kind of doing, doing what's in your, your power.
0:28:07 But yeah, no, just, it, the, just, just an important point, you know what I mean? And I, I, I shared a little bit, um, before we [laughs] hit the record button.
0:28:12 It's like I think for the most part I've done a, a decent job of that through, through my career, but there's definitely, you know, scenarios where, you know, I let m- let the, the sort of the chip on my shoulder get the better of me and, and whatnot.
0:28:22 In retrospect, it's like, ah, I shouldn't have maybe pushed a little bit too, too hard there. So- Mm-hmm... I think it's just valuable if you're listening to this, just be, be cognizant of that.
0:28:29 You know, those, uh, it's a very... It may sound a little bit cliche around not burning bridges, but it's a very real thing. And, uh, you know, this, this is a small space, right? Med tech is relatively small.
0:28:37 And so, uh, you wanna keep those relationships intact.
0:28:41 So, okay, for the sake of time, though, and I, I'm looking at the clock and I wanna be sensitive to your, your schedule, um, Kate, but let's, let's talk about clinical affairs because this is your absolute wheelhouse.
0:28:49 You spent most of your career kind of, you know, running clinical programs. Just completed Target BP1, um, so again, congrats on that. You touched on that.
0:28:56 It's a huge, huge, huge milestone for, for, uh, completing enrollment there. But a lot of med tech, you know, founders and CEOs, they do not have the level of domain expertise in this area a- a- as you do.
0:29:05 So when you, if you were to give them kind of one to two pieces of, of advice, right, for other folks that are, maybe have a, a stronger engineering background or maybe they have a stronger commercial background or whatever, you know, what do they, what do they really need to get right when it comes to, like, planning out their, their, their kind of their, their clinical roadmap?
0:29:20 Yeah. I, I think the simplest way to put it is to ask the right people for input early on.
0:29:30 And, you know, again, this was something I learned fairly early in my career when I was with Eli Lilly and I was in the neuroscience division.
0:29:38 W- we were launching new products left and right, uh, and doing lots of clinical trials.
0:29:42 And one of the things that I learned very early is that you need to be looking ahead, and you need to be looking around the corner when you're designing your clinical trial because after you implement the trial, it's too late to make any changes.
0:29:58 So I would always have somebody from our reimbursement team...
0:30:02 sitting on the clinical trial design committees, uh, and making sure that they were asking us the tough questions, and making sure that, you know, the things that payers might be asking, you know, three, four, five years down the line, if you can, are covered in that clinical trial.
0:30:22 Same goes for the regulators, whether, whether you're talking about FDA or any of the Eur- European agencies. You wanna make sure that you're designing your trial to answer the questions from the people who matter. Mm.
0:30:35 And it's regulatory, it's reimbursement, but it's also the users.
0:30:39 And so making sure you're out there talking to the physicians, you know, the people who will be either prescribing the medication or using your technology, to make sure that your, your trial design is relevant, um, to them, and it resonates for them, and it answers the questions that they're gonna have.
0:30:56 Sounds simple- Right... but, um, sometimes you have to remind yourself of those things. Oh, yeah. Yeah, no doubt.
0:31:02 And a- I, I think kind of this, this idea of sort of managing all of these various stakeholders, I think most people- Mm-hmm...
0:31:08 understand that at a, at a high level, but when they think about, you know, clinical trial design, it's easy to get just caught up in the design itself, right? Mm-hmm. And you forget about, okay, what if this...
0:31:16 At the end of this, this, this study, right, it's a, it's a, it's a huge effort, right? Tons of, you know, tons of resources, pretty long timeline.
0:31:22 You know, when that, when that, when those results kind of are part of a, a dossier, they are in front of someone at, at, you know, some, some large payer, what are they, what is, what's gonna be their feedback, right?
0:31:32 Presuming the data's good, right? Mm-hmm. Is it gonna be enough, right, to convince them that, you know, it's worthy of, you know, coverage and coverage re- re- reimbursement?
0:31:39 But, um, yeah, I mean, that's, that's a, that's a good reminder that, you know, there's... Be, be thinking about all of those, those key stakeholders early on, right? Mm-hmm.
0:31:47 As you're planning, planning that, that, that trial. I love your analogy of the, the, the, uh, the soufflé as well, right?
0:31:52 [laughs] It's like, kind of reminds me, like you, you, you invest in like a, a really nice, you know, piece of, uh, piece of meat or something like that.
0:31:58 It's like, well, if you, if you mess up all of the prep, right, uh, it doesn't matter how, how it's grilled, right? It's li- likely gonna be- Yeah... less, not gonna turn out great.
0:32:05 But, uh, the same, same general concept with trial, trial design. It's like you better, better be doing the work up front, um- Right...
0:32:11 you know, 'cause otherwise you're, you're not setting yourself up for, for s- for success. Um, no, that, that, that's good.
0:32:15 And so kind of on the, on this topic, right, since regulatory, there's so much overlap, right- Mm-hmm...
0:32:19 with, with reg and, and clinical, and you mentioned that you need to make sure that like the, the regulatory folks are involved in the clinical trial design because, you know, they're gonna be the best...
0:32:27 They're gonna have the best idea of what the agencies, the regulatory agencies are gonna be g- gonna be looking for.
0:32:33 So when you think about kind of the overlap between the two, what do, what do other med tech founders and CEOs really need to get right, you know?
0:32:38 Or maybe, maybe, or, and alternatively maybe frame it up against like what do you often see them doing wrong [laughs] when it comes to, when it comes to kind of the, the topic of, of regulatory affairs?
0:32:48 I think the, the biggest thing is never to assume. Mm. So, uh, you know, especially on the device side, CDRH has been very good, uh, in, in, uh, granting people breakthrough designation.
0:33:03 And with that, you have an open invitation to talk to them early and often. And so don't just assume, well, the FDA is gonna say this, or the FDA is gonna think this. Actually ask them. Hmm.
0:33:16 Um, and don't be afraid to have that conversation because, you know, that's what they're there for. Um, and, and have that, that ongoing dialogue and that ongoing communication. Right.
0:33:26 It seems like that comes up so, so often, right?
0:33:28 And it, it must come up so often because it happens probably quite a bit, right, where, where founders, uh, founders or CEOs, um, you know, they just, they're, they're looking for a hack, right, or a workaround, and they simply don't take advantage of just, uh, you know, just having, you know, opening up conversation with, uh, with FDA.
0:33:44 And I, I remember a conver- uh, a discussion I had with, um, Rosina Samadali, I think. I, I'm, I might be mispronouncing her last name, but she's the CEO of, um, of a device for, um, uh, concussions.
0:33:55 It's like, I think the device name is iBox, I believe. It's I- Occulogica, I think is the, is the company name.
0:33:59 But she mentioned, she was like, you know, one of the, one of the things that I think a lot of people get wrong too as they engage with FDA is that they don't realize it's another human being on the other side of the table, right?
0:34:07 They're gonna want... They, they need to know certain things. They're gonna have certain questions. Of course, that's obvious. But you know, they, they, they're a person at the end of the day, right? Yeah.
0:34:13 And you know, you need to kind of, you know, treat the relationship as, as such.
0:34:17 Um, and so I think that that's a, that was, you know, a really, really helpful, you know, reminder that, uh, you know, engage early and often, but also, you know, these, these are just other, other people [laughs] kind of trying to do their jobs too.
0:34:26 Yeah. Yeah. And, and, and like in any negotiation, you, you need to try to understand where they're coming from- Mm-hmm... and what their vantage point is, and why are they asking you these questions.
0:34:36 Is it that you haven't provided them enough details or, um, you know, is there confusion about what it is that you're asking for?
0:34:45 Um, so you know, asking those, those questions and, and trying to get, get to the crux of it. Mm-hmm. Yep. That's, uh, that's, that's good stuff.
0:34:53 Um, let's jump to, to fundra- I'm looking at the clock and I wanna leave enough time for the kind of the rapid fire portion of this interview.
0:34:58 [laughs] Um, but before we get to financing, just real quickly on reimbursement, right? Because you're dealing with a technology I don't think has exist- there's no s- existing CPT codes, right?
0:35:06 I mean, for, for- Um, there, there are CPT III codes currently, but- Oh, there are? Okay. Yeah. Got it.
0:35:12 So when, when you think about how the clin reg strategy kind of layer- layers up to, to coverage and reimbursement, that's such a huge hurdle that I think a lot of founders don't think about early.
0:35:23 Um, es- i- i- especially as they're, you know, they're, they're in the e- e- in the earliest stages of a, of a, of a project evaluating whether or not it makes sense to kind of, you know, con- continue forward is like, is this reimburs- you know, is this covered right now, uh, under- Mm...
0:35:35 under certain codes? Under, does it fall under DRG, et cetera? They just don't think about it en- en- enough. Um, if you had to kind of summarize your thoughts on how to...
0:35:43 O- on reimbursement in general, and how important it is, and what it takes, you know, uh, to actually, you know, see coverage and reimbursement, and it... That's, that's, that's compelling enough, right?
0:35:52 Uh, where it makes sense- Mm-hmm... to economic stakeholders. You know, what's your, what's your kind of general advice for other, other founders and, and CEOs that are dealing with this?
0:35:58 You know, it's hard to, to give general advice because reimbursement is so different depending- Mm... on the technology. Um, as you said, you know, some have existing codes they can, they can piggyback onto.
0:36:10 Some have to, you know- Uh, y- you know, cli- climb the mountain [laughs] uh, in order to get there.
0:36:18 Uh, and then, you know, just the healthcare e- uh, system in, in general has, has gotten so interesting as far as self-pay markets and- Mm... you know, all sorts of other things.
0:36:28 So I, I, I don't think that there's a one-size fit- fits-all, uh, piece of advice other than to say you've gotta do your homework early.
0:36:37 And I know you wanna talk about fundraising, but you have to, you have to be able to answer the investors- Mm... because they're gonna ask you, "What's your reimbursement strategy?"
0:36:47 And so it maybe doesn't have to be fully baked. Um, certainly it's not gonna be done.
0:36:54 Uh, you know, reimbursement is kind of the last piece, but, but you have to have a strategy, and you have to know what the landscape is.
0:37:02 Um, and, and you have to know what your plan is at least, you know, at the 30,000-foot view- Mm-hmm... um, because you're gonna get asked about it. Yeah, you're right.
0:37:10 And, and whether it's a, you know, a seed stage investor or maybe a more sophisticated Series A, B or C investor, they ask that question, "Well, who, who's gonna, who's gonna pay for this really cool technology-" Mm-hmm...
0:37:19 "that you're developing?" And your response is, you know, uh, deer in headlights, it's likely not gonna [laughs] not gonna be an effective pitch, right?
0:37:26 Or end with, end with them, uh, you know, giving or write- writing you a check. So yeah, that's a, that- that's a good take. But, uh, it's, it's also a nice transition to talk a little bit more about fundraising, right?
0:37:34 Yeah. So you, I think, um, based on my research, Ablativ closed on the fourth tranche of your, of your Series D about a year ago maybe, a little less than, less than a year ago. It was mid 2022 or so.
0:37:45 Fundraising is, is incredibly difficult, especially in this e- macroeconomic en- en- environment.
0:37:49 It's arg- arguably maybe, you know, one of the most difficult things any, any, any startup has to do, is, you know, convince people to, you know, write, write, write them checks.
0:37:57 You know, when you think about kind of your involvement in raising funds for, for Ablativ, what are some of the, the key things that you've, you've learned along the way? Yeah.
0:38:05 So, uh, I- I'll open it up just a little bit because obviously I did fundraising at NeoSync- Mm... uh, and then with Ablativ Solutions. Um, in both of those situations, uh, it was a little bit different.
0:38:16 So at NeoSync, um, I had two very strong, uh, early stage investors.
0:38:22 When I rejoined them as CEO, we decided we wanted to bring in a third investor to, to really kind of establish the value or reestablish the value of the company. It was in the psychiatry space.
0:38:35 Uh, nobody wanted to invest in psychiatry devices of all things. Um, and so I really, it, it, that was where I really learned how to fundraise, uh, which I think prepared me for Ablativ Solutions, uh, as a result of it.
0:38:51 Um, you know, I, I went out, I pitched to anybody who would listen to me. I perfected my elevator speech.
0:38:59 I understood more from the rejections than the second meetings of what is important to investors and what, what they wanna understand, and how do you articulate that in a way that, you know, you...
0:39:14 in, in 10 minutes, you know, you can answer all of their questions, um, or tell them, "I don't have the answer to that question right now," you know, and be honest about that. Mm.
0:39:26 So that really kind of, fast-forward, prepared me for my time at Ablativ Solutions.
0:39:32 You know, I've been blessed that we have a really great syndicate of investors that joined us in Series D, as well as, you know, uh, family funds and, uh, S- Series A, uh, and, and B investors that have really stuck with us, uh, through it all because they believe in the technology.
0:39:51 Um, but for me, I had to deliver. Mm-hmm. You know?
0:39:55 Uh, I made a commitment to these investors, and we had specific deliverables for each of these tranches in Series D, and so I had to execute, and I had to, uh, you know, continue to show them that, uh, we are delivering and we are spending their money wisely.
0:40:14 Of course, I took over as CEO in 2019, never expecting we would be hit with a global pandemic, uh, that shut our pivotal trial down, uh, and, you know, impacted our, our, our studies, uh, i- in the way that it did.
0:40:30 Um, so we have had to do, uh, some bridge funding.
0:40:34 But again, it's, you know, communicating with our investors, communicating with our board, uh, and making sure that, that we have a very clear, uh, operating plan with goals and deliverables, and that we achieve those, those deliverables, uh, and, and continue to, to move the company forward, and to continue to create value for our investors.
0:40:59 Mm-hmm. Um, and so, you know, I'm looking forward to the next year,
0:41:04 uh, when we do have our pivotal data, uh, when we likely will be opening things up, uh, to other outside investors, uh, that are interested as we prepare for, for commercialization and launch, uh, once we're approved.
0:41:17 Um, and so I'm looking forward to, to that time, uh, because I think we've got a pretty compelling story. Yeah. Yeah, no doubt. No doubt. Yeah.
0:41:24 And I think, um, I, I wanna leave enough r- uh, time for the rapid fire portion of this, this interview, but, um, hearing you kind of describe, right, the, the experience at, at, uh, at, the fundraising experiences at two different companies at a, at a high level, it reminds me of, of just how important, um, communication, right, is to these in- Mm-hmm...
0:41:39 to, to, to the various people that, that are, you know, you know, write- writing, you know, writing, writing checks, whether they do this for a living or whether they, uh, you know, they're writing personal checks because they, they believe in the, in the story and what you're developing.
0:41:49 But if you're up against an unforeseen, you know, issue, which I don't wanna underappreciate in, in, in COVID, that's obviously gonna impact, right, your, your, your, uh, your, your, your milestones, right, that you've been, you've been targeting.
0:42:01 Mm-hmm.
0:42:01 But I, I would presume, I'm gonna presume that because you had so m- you know, all of your b- investors basically followed up in these, in these later, you know, rounds and tranches, you probably were pretty effective at communicating what, what you're up against, how you're solving for those issues, and that just reassures them that, hey, you're not gonna, you're gonna be- You're gonna j- spending their, spending the...
0:42:18 Deploying their, their money wisely, right? To, uh, you know, in, in the, in the face of some obstacles. And I just think that's...
0:42:23 You know, for anyone listening, it's how you're managing that process and running it speaks volumes.
0:42:28 Um, you know, 'cause if your response times are delayed, or if you don't follow up, and it's like all of these little signals that, you know, your investors are gonna lose confidence, right?
0:42:36 But if you're doing the opposite and communicating- Mm-hmm... at a high level, being responsive, you know, you know, that's obviously gonna lead to, lead to outcomes like, like you've experienced, right?
0:42:43 Where so many, so many people are like, "Yeah, I'm gonna... I'm, I'm good. I'm gonna write you another check," right? I'm, I'm following up- Right... with, with my investment. So that's good stuff.
0:42:50 So, uh, we've got, you know, a few minutes left here in the, in the conversation. Um, let's jump to the rapid fire portion of this interview. Um, Kate, questions are rapid fire in nature.
0:42:58 If you wanna expand a little bit, that's to- that's totally fine.
0:43:00 Um, but first question, specific to Ablativ, you, you mentioned this a little bit, but, like, looking out over the next, let's call it 12 to 18 months, what's the thing that, you know, uh, gets you most hyped up about, about, uh, uh, what's going on at, at the company?
0:43:12 Uh, a- as I mentioned before, it's, it's, uh, you know, waiting for the souffle to cook, waiting for our- [laughs]...
0:43:18 pivotal trial data to, to be available, uh, after the follow-up and, and being able to get it into the FDA, uh, you know, review, uh, cycle.
0:43:27 And then, uh, being able to build our, uh, our commercial plan and, and execute it. Yeah. That's... Yeah, a lot of, of good stuff. Although probably, probably a little bit, a little bit of, uh, a- anxiety, right?
0:43:38 Waiting for the souffle to cook. [laughs] The, the, uh- Mm-hmm. But you're, you're smiling. I get a sense maybe the, the, the data's gonna be strong. I don't know. Just kn- know- Well, I don't know...
0:43:45 knowing you a little bit, I mean, we- The, the study's blinded. I have no idea. So, um, we, we will, we will wait and see. But, um, you know, I'm- I-... I'm excited about it. Yeah.
0:43:54 I, I, I have a hunch it's gonna turn out real well. I know that, I know that our team and our physician partners have done everything they can to run- Mm...
0:44:02 uh, you know, the most scientifically sound program, that they've been able... you know, that, that we could. Um, and so I feel good about it. Yeah, yeah. It's all you can do, right? Like, control the- Mm-hmm...
0:44:12 control the controllables. Uh, I have a hunch, I have a suspicion that it's gonna be, it's gonna be positive. We'll cer- certainly be, uh, rooting for the, for the team for sure, uh, from, from the sidelines here.
0:44:21 So since joining, uh, at Ablativ, uh, as, as CEO back in 2019, what's the, what's the single, uh, biggest sort of thing that you've, you've learned over the, the last, you know, four plus years?
0:44:33 Uh, well, uh, we touched on it. So of course, uh, this, this position will go down in history as, you know, leading a, a, a company through, uh, through COVID.
0:44:43 But I think, y- you know, for me, it was just reinforcing, uh, never to assume that things are gonna go as planned. Hmm.
0:44:51 Um, and always to, to be thinking about contingencies and, um, as I like to say, looking around the corner. Yeah.
0:44:59 You know, what, what, what's the next challenge gonna be, and what can we do to make sure that we have a plan B, uh, just in case things don't go as planned? Right. Right.
0:45:08 Uh, so, so crucial, especially for an early, you know, early stage company that's- Mm-hmm... you know, trying to, trying to de- uh, develop a, a, a, a, a novel compelling technology. Yeah.
0:45:17 [laughs] Nothing's ever guaranteed and need to be, need to be looking around the corner as you, as, uh, as you put it. Um, all right. So let's, let's set, set the stage here.
0:45:25 Um, maybe you're in Boston, or maybe you're back kind of in, in Southern California, you know, near, near NeoSync. You just presented in front of, like, 2, 300 entrepreneurs on stage, and they, uh...
0:45:34 You wanna leave them with, with one thing that they really need to understand, what would that, what would that be? I would have to say, I think, uh, the same as my answer to my last one, which is don't assume. Hmm.
0:45:45 Right? So always be thinking ahead and, and surround yourself with people that are gonna challenge you. Uh, and, and don't just, you know, uh, take for granted, uh, everything at face value.
0:45:58 Um, you need to constantly be challenge- challenging yourselves and thinking about what ifs, uh, and, uh, as, as you embark on that journey. Hmm. Good stuff.
0:46:07 Second to last question here is, um, are there any other, um, you know, med tech, life science, you know, entrepreneurs, founders that, uh, that you find inspiring or wanna, wanna maybe mention while we're recording this?
0:46:18 Oh, that's a tough one. Mm-hmm. There's a lot of good ones out there. You know, I've been following Shockwave, uh, since my days at Covidien. Mm-hmm.
0:46:27 I, I remember, uh, when they were really just starting out, and, uh, uh, I think if I had one, I had 100 physicians say, "You guys need to buy them." [laughs] We didn't.
0:46:39 Um, but I think Doug has really done a great job in, in creating value, uh, with that organization and, and, uh, I've been cheering them on from the sidelines for, for quite some time. Yeah. Pretty, pretty rare story.
0:46:51 I mean, their, their, uh, their ability to execute with a pretty narrow portfolio of, of devices, you just don't see it very often, you know? Yeah. And so, uh, yeah. Good one to, to, to watch for sure. Um, all right.
0:47:02 Yeah. Last question, Kate. Starting over in, let's frame it up around kind of your maybe mid to late 20s, right? Early in your career, but not, you know, but you've got some experience under your belt.
0:47:11 You know, is there, is there a piece of advice, right, that you'd... if you could go back in time and, and tell your, your younger self from a pro- professional standpoint, what would, what would that be? Yeah.
0:47:20 I'd say don't stress. Don't stress about it. Don't... You know, you don't necessarily have to have your entire career planned out.
0:47:28 You know, as I mentioned at the beginning of, of, of our discussion, I thought I was gonna be a neurosurgeon. I ended up being a CEO of a med tech company. Hmm. So, uh, and, and I had quite a journey along the way.
0:47:39 And, you know, you need to stay true to yourself, but you also need to know what's important to you.
0:47:46 And so each time you make a decision to make a move, you need to know when the right time is right, but also what that next move is going to be. And it may not be anything that you thought you would wanna do.
0:47:59 I, case in point, never in my career thought I was, uh, wanted to be a CEO. Was never an aspiration of mine, but I love my job, and I love what I do, and I love the people I work with. So never say never.
0:48:13 That's a good, good, good way to end the conversation. Um, for everyone listening, Ablativ Solutions, uh, is the, is the company that Ka- Kate's running as a, a CEO. Ablativsolutions.com is the website.
0:48:23 We'll of course link to it in the full summary piece on, on MedSider. We'll also link to, uh, Kate's LinkedIn profile if you wanna, uh, reach out directly to her. Um, but, uh, I know we're up against the clock.
0:48:32 I wanna be sensitive to your s- your schedule, uh, Kate. Can't thank you enough for, for coming on.
0:48:35 This has been a, a fun opportunity to kind of re- regroup and catch up on what, what you've been doing over the past, uh, past five years or so. Yeah, absolutely. It's been fun. Let's not wait so long next time.
0:48:44 [laughs] I know. Yeah. Right on. Right on. Yeah. I'll have you hold on the line, uh, real quick. But again, everyone that's listened this far, thanks for your attention as always.
0:48:51 Um, until the next episode of MedSider Goes Live, everyone, uh, take care. [upbeat music]
